Jove
Visualize
Contact Us

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Primary Lymphoid Organs01:16

Primary Lymphoid Organs

Primary lymphoid organs are pivotal in the formation, development, and maturation of lymphocytes, the white blood cells that serve as the backbone of our immune system. This crucial function underscores their fundamental role in maintaining our overall health and immunity. The two primary lymphoid organs of prime importance are the red bone marrow and the thymus.
The red bone marrow is a soft, spongy tissue nestled in the interior of long bones such as the humerus and femur. It is the site...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Consolidation Therapy with Checkpoint Inhibitors After Autologous Hematopoietic Cell Transplantation in Patients with High-Risk Multiple Myeloma and Lymphoma.

Transplantation and cellular therapy·2026
Same author

Five-year follow-up of patients with relapsed/refractory mantle cell lymphoma treated with anti-CD19 CAR T-cell therapy in ZUMA-2, Cohorts 1 and 2.

Journal of hematology & oncology·2026
Same author

Outcomes of Salvage Therapy after Early-Line CD19 Chimeric Antigen Receptor T-Cell Failure in Large B-Cell Lymphoma.

Transplantation and cellular therapy·2026
Same author

The clinical applications of next-generation sequencing and ctDNA/cfDNA in lymphoma.

Clinical advances in hematology & oncology : H&O·2026
Same author

CD19 CAR T-Cell Therapy in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type.

American journal of hematology·2026
Same author

Time of day of CAR T-cell infusion and outcomes in large B-cell lymphoma.

Blood·2026
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Jul 13, 2026

Bioprinting of Hydrogel Tumor Slices as a 3D Model for Mantle Cell Lymphoma
08:31

Bioprinting of Hydrogel Tumor Slices as a 3D Model for Mantle Cell Lymphoma

Published on: September 12, 2025

Mantle cell lymphoma: evolving novel options.

Andre Goy1

  • 1Lymphoma Division, Hackensack Medical University Cancer Center, 20 Prospect Avenue, Hackensack, NJ 07601, USA. agoy@humed.com

Current Oncology Reports
|August 21, 2007
PubMed
Summary
This summary is machine-generated.

Mantle cell lymphoma (MCL) treatment is evolving with intensified front-line therapies and novel agents for relapsed patients. Research focuses on targeted therapies and molecular approaches to improve outcomes in this challenging non-Hodgkin

More Related Videos

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma
10:52

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma

Published on: March 30, 2018

Related Experiment Videos

Last Updated: Jul 13, 2026

Bioprinting of Hydrogel Tumor Slices as a 3D Model for Mantle Cell Lymphoma
08:31

Bioprinting of Hydrogel Tumor Slices as a 3D Model for Mantle Cell Lymphoma

Published on: September 12, 2025

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma
10:52

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma

Published on: March 30, 2018

Area of Science:

  • Hematology
  • Oncology
  • Clinical Investigation

Background:

  • Mantle cell lymphoma (MCL) is a rare non-Hodgkin's lymphoma subtype, comprising 6% of cases.
  • Despite active clinical investigation, no definitive standard therapy exists, and most patients experience relapse.
  • Current front-line therapy strategies involve intensified regimens, including high-dose therapy with stem cell transplant or dose-intense chemotherapy (hyper-CVAD) with rituximab.

Purpose of the Study:

  • To review the current landscape of mantle cell lymphoma treatment.
  • To highlight novel therapeutic agents and molecular approaches under investigation.
  • To discuss future directions in clinical trials for MCL.

Main Methods:

  • Review of current clinical investigations and therapeutic strategies for mantle cell lymphoma.
  • Analysis of novel agents, including biologic agents and targeted therapies.
  • Exploration of emerging molecular approaches such as pharmacogenomics.

Main Results:

  • Bortezomib, a proteasome inhibitor, is the first approved agent for relapsed/refractory MCL.
  • Various small molecules, including mTOR and Bcl-2 inhibitors, demonstrate encouraging activity.
  • Novel antibodies and new cytotoxic agents are under active investigation.

Conclusions:

  • Intensified front-line therapy may benefit patients with mantle cell lymphoma.
  • A growing number of novel agents show promise for relapsed/refractory disease.
  • Future mantle cell lymphoma trials will likely incorporate pharmacogenomic strategies for personalized medicine.